Taba H, Kusano N
First Department of Internal Medicine, Faculty of Medicine, University of the Ryukyus, 207 Uehara, Nishihara, Okinawa 903-0215, Japan.
Antimicrob Agents Chemother. 1998 Sep;42(9):2193-6. doi: 10.1128/AAC.42.9.2193.
Antimicrobial susceptibility testing revealed among 150 clinical isolates of Streptococcus pneumoniae 4 pneumococcal isolates with resistance to fluoroquinolones (MIC of ciprofloxacin, >/=32 microgram/ml; MIC of sparfloxacin, >/=16 microgram/ml). Gene amplification and sequencing analysis of gyrA and parC revealed nucleotide changes leading to amino acid substitutions in both GyrA and ParC of all four fluoroquinolone-resistant isolates. In the case of strains 182 and 674 for which sparfloxacin MICs were 16 and 64 microgram/ml, respectively, nucleotide changes were detected at codon 81 in gyrA and codon 79 in parC; these changes led to an Ser-->Phe substitution in GyrA and an Ser-->Phe substitution in ParC. Strains 354 and 252, for which sparfloxacin MICs were 128 microgram/ml, revealed multiple mutations in both gyrA and parC. These strains exhibited nucleotide changes at codon 85 leading to a Glu-->Lys substitution in GyrA, in addition to Ser-79-->Tyr and Lys-137-->Asn substitutions in ParC. Moreover, strain 252 showed additional nucleotide changes at codon 93, which led to a Trp-->Arg substitution in GyrA. These results suggest that sparfloxacin resistance could be due to the multiple mutations in GyrA and ParC. However, it is possible that other yet unidentified mutations may also be involved in the high-level resistance to fluoroquinolones in S. pneumoniae.
对150株肺炎链球菌临床分离株进行的药敏试验显示,有4株肺炎球菌分离株对氟喹诺酮类耐药(环丙沙星的MIC≥32微克/毫升;司帕沙星的MIC≥16微克/毫升)。对gyrA和parC进行基因扩增和测序分析发现,所有4株氟喹诺酮耐药分离株的GyrA和ParC中均有导致氨基酸替代的核苷酸变化。对于司帕沙星MIC分别为16和64微克/毫升的182和674菌株,在gyrA的第81密码子和parC的第79密码子检测到核苷酸变化;这些变化导致GyrA中Ser→Phe替代和ParC中Ser→Phe替代。司帕沙星MIC为128微克/毫升的354和252菌株在gyrA和parC中均显示多个突变。这些菌株在第85密码子处出现核苷酸变化,导致GyrA中Glu→Lys替代,此外ParC中Ser-79→Tyr和Lys-137→Asn替代。此外,252菌株在第93密码子处还显示额外的核苷酸变化,导致GyrA中Trp→Arg替代。这些结果表明,司帕沙星耐药可能是由于GyrA和ParC中的多个突变。然而,其他尚未鉴定的突变也可能参与肺炎链球菌对氟喹诺酮类的高水平耐药。